Alumis (ALMS) to Release Earnings on Wednesday

Alumis (NASDAQ:ALMS) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($1.40) per share for the quarter.

Alumis Trading Up 0.6 %

NASDAQ:ALMS opened at $5.13 on Friday. The stock has a 50 day moving average of $7.18 and a two-hundred day moving average of $9.75. Alumis has a 12 month low of $4.74 and a 12 month high of $13.53.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ALMS. Oppenheimer initiated coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price for the company. HC Wainwright decreased their price target on shares of Alumis from $26.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Alumis currently has an average rating of “Buy” and a consensus target price of $26.57.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.